Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024

Oslo, 30 April 2024, the Board of Directors hereby calls for the Annual General Meeting of Lytix Biopharma AS (the "Company") in Sandakerveien 130, 0484 Oslo, Norway at 13:00 Hours (CEST) on 14 May 2024.

All documents regarding the Annual General Meeting are available at the Company's website: www.lytixbiopharma.com.

For further information, please see the Company’s website or contact CFO Gjest Breistein. Please see below for contact details.

Gjest Breistein, CFO

E-mail: [email protected]

Phone: +47 952 60 512

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.